Everolimus after failure of sorafenib did not improve survival of patients with advanced hepatocellular carcinoma
(dailyRx News) Even when new medications show a lot of promise in the
early stages of testing, they don't always prove to work so well in
later stages of testing. For certain liver cancer patients, everolimus (Afinitor) may be less effective against tumors than previously thought.
In a recent trial, everolimus did not boost survival compared to
placebo (mock medication) in patients with an advanced form of liver
cancer.
Andrew Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center and Harvard Medical School in Boston, was this study's lead author.
Read more...Labels: everolimus, Liver cancer HCC, sorafenib